Quarterly report pursuant to Section 13 or 15(d)

Stock Options and Restricted Stock Units

v3.7.0.1
Stock Options and Restricted Stock Units
3 Months Ended
Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Options and Restricted Stock Units

NOTE 10 – STOCK OPTIONS AND RESTRICTED STOCK UNITS

 

On July 31, 2014, the Board of Directors of Q2P approved the Founders Stock Option Plan (“Founders Plan”) and the 2014 Employee Stock Option Plan (the “2014 Plan”), collectively the “Option Plans”. The Option Plans were developed to provide a means whereby directors and selected employees, officers, consultants, and advisors of the Company may be granted incentive or non-qualified stock options to purchase restricted common stock of the Company. On February 25, 2016, to accommodate the appointment of new Board members and additional incentive stock options and stock grants to key employees of the Company, the Board approved the 2016 Omnibus Equity Incentive Plan (“2016 Plan”), which allowed for an additional 4 million shares of common stock, stock options, stock rights (restricted stock units), or stock appreciation rights to be granted by the Board in its discretion.

 

For the three months ended March 31, 2017, the charge to the condensed consolidated statement of operations for the amortization of stock option grants awarded under the Option Plans and 2016 Plan was $34,608. The remaining unamortized stock option expense for all outstanding stock options at March 31, 2017 was $107,982.

 

A summary of the common stock options issued under the Option Plans and the 2016 Plan for the period from December 31, 2016 through March 31, 2017 follows:

 

    Number Outstanding     Weighted Avg. Exercise Price     Weighted Avg. Remaining Contractual Life (Years)  
Balance, December 31, 2016     6,115,480     $ 0.21       6.1  
Options issued                      
Options exercised                      
Options cancelled                      
Balance, March 31, 2017     6,115,480     $ 0.21       5.9  

 

The vested and exercisable options at period end follows:

 

    Exercisable/ Vested Options Outstanding     Weighted Avg. Exercise Price     Weighted Avg. Remaining Contractual Life (Years)  
Balance, March 31, 2017     4,992,147     $ 0.21       5.9